Stay updated on Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.

Latest updates to the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe record describes a completed Phase 1/2 study of nivolumab combined with a PD-L1/IDO peptide vaccine for metastatic melanoma, including its participant criteria, treatment schedule, and measured outcomes. It also provides study publications, investigator details, and a study protocol document.SummaryDifference52%

- Check15 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner was added announcing an NIH website transition and linking to updates and FAQs. It appears above the 403 error page.SummaryDifference1%

- Check29 days agoChange DetectedThe displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content and navigation for this URL. Access to the study details is blocked.SummaryDifference19%

Stay in the know with updates to Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combination Nivolumab & PD-L1/IDO Vaccine in Melanoma Clinical Trial page.